Prognostic impact of eosinophils in mastocytosis: analysis of 2350 patients collected in the ECNM Registry
暂无分享,去创建一个
M. Triggiani | J. Panse | H. Kluin-Nelemans | T. Jakob | D. Niederwieser | A. Reiter | P. Valent | W. Sperr | A. Zink | P. Bonadonna | J. Rossignol | J. Gotlib | O. Hermine | C. Breynaert | O. Lortholary | L. Malcovati | K. Brockow | M. Arock | K. Hartmann | E. Aberer | N. von Bubnoff | J. Schwaab | A. Yavuz | M. Doubek | M. Mattsson | V. Sabato | M. Niedoszytko | M. Jawhar | C. Elena | L. Span | L. Scaffidi | R. Zanotti | F. Caroppo | A. B. Fortina | J. Várkonyi | D. Fuchs | R. Parente | A. Górska | K. Shoumariyeh | H. Hagglund | M. Lange | C. Perkins | B. van Anrooij | A. Illerhaus | Alex Kilbertus | A. Fortina | Vanessa E. Kennedy
[1] Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of PDGFRA, PDGFRB, or FGFR1, or with PCM1-JAK2 , 2020, Definitions.
[2] M. Triggiani,et al. The Data Registry of the European Competence Network on Mastocytosis (ECNM): Set Up, Projects, and Perspectives. , 2019, The journal of allergy and clinical immunology. In practice.
[3] J. Butterfield,et al. Mast Cell Mediators of Significance in Clinical Practice in Mastocytosis. , 2018, Immunology and allergy clinics of North America.
[4] A. Órfão,et al. Characterization of CD34+ hematopoietic cells in systemic mastocytosis: Potential role in disease dissemination , 2018, Allergy.
[5] G. Nilsson,et al. Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future. , 2017, Cancer research.
[6] W. Hofmann,et al. KIT D816V and JAK2 V617F mutations are seen recurrently in hypereosinophilia of unknown significance , 2015, American journal of hematology.
[7] P. Valent,et al. Mast Cells, Mastocytosis, and Related Disorders. , 2015, The New England journal of medicine.
[8] M. Triggiani,et al. KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis , 2015, Leukemia.
[9] P. Weller,et al. Eosinophilia in mast cell disease. , 2014, Immunology and allergy clinics of North America.
[10] T. Haferlach,et al. Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. , 2012, The Journal of allergy and clinical immunology.
[11] Torsten Haferlach,et al. Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field , 2012, Expert review of hematology.
[12] H. Kluin-Nelemans,et al. The classification of systemic mastocytosis should include mast cell leukemia (MCL) and systemic mastocytosis with a clonal hematologic non-mast cell lineage disease (SM-AHNMD). , 2010, Blood.
[13] K. Sotlar,et al. Variable presence of KITD816V in clonal haematological non‐mast cell lineage diseases associated with systemic mastocytosis (SM–AHNMD) , 2010, The Journal of pathology.
[14] A. Tefferi,et al. Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies. , 2009, Blood.
[15] R. Yeh,et al. The molecular anatomy of the FIP1L1-PDGFRA fusion gene , 2009, Leukemia.
[16] D. Metcalfe. Mast cells and mastocytosis. , 2008, Blood.
[17] P. Weller,et al. Immunoregulatory roles of eosinophils: a new look at a familiar cell , 2008, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[18] N. Shinton. WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues , 2007 .
[19] M. Fay,et al. KIT D816V-associated systemic mastocytosis with eosinophilia and FIP1L1/PDGFRA-associated chronic eosinophilic leukemia are distinct entities. , 2007, The Journal of allergy and clinical immunology.
[20] O. Haas,et al. Eosinophilia in systemic mastocytosis: clinical and molecular correlates and prognostic significance. , 2007, The Journal of allergy and clinical immunology.
[21] M. Triggiani,et al. Standards and standardization in mastocytosis: Consensus Statements on Diagnostics, Treatment Recommendations and Response Criteria , 2007, European journal of clinical investigation.
[22] A. Órfão,et al. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. , 2006, Blood.
[23] J. Butterfield. Systemic mastocytosis: clinical manifestations and differential diagnosis. , 2006, Immunology and allergy clinics of North America.
[24] A. Tefferi,et al. Eosinophils are derived from the neoplastic clone in patients with systemic mastocytosis and eosinophilia. , 2003, Leukemia research.
[25] L. Scott,et al. Analysis of the surface expression of c-kit and occurrence of the c-kit Asp816Val activating mutation in T cells, B cells, and myelomonocytic cells in patients with mastocytosis. , 2000, Experimental hematology.
[26] D. Metcalfe,et al. Elevated expression of the proto-oncogene c-kit in patients with mastocytosis , 1998, Leukemia.
[27] Laura H. Tang,et al. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm , 1996, Nature Genetics.
[28] W. Travis,et al. Hematologic manifestations of systemic mast cell disease: a prospective study of laboratory and morphologic features and their relation to prognosis. , 1991, The American journal of medicine.
[29] P. Weller,et al. The immunobiology of eosinophils. , 1991, The New England journal of medicine.
[30] D. Metcalfe. The liver, spleen, and lymph nodes in mastocytosis. , 1991, The Journal of investigative dermatology.
[31] D. Metcalfe,et al. Classification and diagnosis of mastocytosis: current status. , 1991, The Journal of investigative dermatology.
[32] E. Bergstralh,et al. Systemic Mast Cell Disease: ANALYSIS OF 58 CASES AND LITERATURE REVIEW , 1988, Medicine.
[33] J. Higginson,et al. International Agency for Research on Cancer. , 1968, WHO chronicle.